View all news

Exicure, Inc. To Begin Trading on United States OTCQB® Under the Symbol “XCUR”


SKOKIE, Ill.--(BUSINESS WIRE)--May 23, 2018-- Exicure, Inc. (OTC:XCUR), the pioneer in the development and application of three-dimensional Spherical Nucleic Acid (SNA™) constructs as gene regulatory and immunotherapeutic agents, is pleased to announce the commencement of the public trading of its common stock. The Company will trade under the ticker “XCUR” effective as of market open on Thursday May 24th, 2018. The Company expects to be quoted on the OTCQB® Venture Market imminently.

“This is an exciting day for Exicure,” said Dr. David Giljohann, CEO of Exicure. “We have developed and applied our proprietary 3-dimensional spherical nucleic acid architecture to multiple clinical programs and a growing pipeline of new drug candidates. We continue to be focused on using our SNA technology to rapidly develop new targeted drugs for patients with unmet medical needs.”

Exicure’s lead programs are in oncology, genetic disorders, and inflammatory diseases.

Corporate Progress

  • A Phase 1 clinical trial of AST-008 began dosing in the fourth quarter of 2017. AST-008 is a TLR9 agonist for immuno-oncology applications. Exicure received authorization from Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom to conduct a Phase 1 clinical trial of AST-008 in the United Kingdom. Our current plan anticipates launching a Phase 1b/2 clinical trial for AST-008 late this year.
  • Dosing began in the Phase 1 clinical trial of XCUR17 in the second quarter of 2018. XCUR17 is a topically-applied inhibitor of IL-17RA, a key mediator of inflammation. This trial is designed to test safety and efficacy of the drug. Twenty-five patients will be enrolled and treated for a 26-day dosing period. We expect trial data during the third quarter of this year.
  • Exicure will present pre-clinical data utilizing an SNA designed for the treatment of spinal muscular atrophy (SMA). Our data suggest that the SNA architecture may have superior pharmacodynamic properties compared to other nucleic acid therapeutic designs. Exicure will present pre-clinical data at the upcoming Cure SMA Researcher Meeting in Dallas, Texas on June 14th, 2018.

About Exicure, Inc.

Exicure, Inc. is a clinical stage biotechnology company developing a new class of immunomodulatory and gene regulating drugs against validated targets. Exicure's proprietary 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of therapeutic oligonucleotides in a wide range of cells and tissues. Exicure's lead programs address inflammatory diseases, genetic disorders and oncology. Exicure is based outside of Chicago,

Forward Looking Statements

This press release contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning the Company, expected listing and trading on OTCQB® Venture Market, the Company’s technology, potential therapies, clinical and regulatory objectives and other matters. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “plan,” “believe,” “intend,” “look forward,” and other similar expressions among others. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: that Exicure’s pre-clinical programs do not advance into the clinic or result in approved products on a timely or cost effective basis or at all; regulatory developments; and the ability of Exicure to protect its intellectual property rights. Exicure’s pipeline programs are in various stages of pre-clinical and clinical development, and the process by which such pre-clinical or clinical therapeutic candidates could potentially lead to an approved therapeutic is long and subject to significant risks and uncertainties. Risks facing the Company and its programs are set forth in the Company’s filings with the SEC. Except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Source: Exicure, Inc.

MacDougall Biomedical Communications
Karen Sharma, 781-235-3060
The Del Mar Consulting Group, Inc.
Robert B. Prag, 858-794-9500

Multimedia Files:

Categories: Press Releases
View all news